Last updated on January 2020

Evaluation of Ocoxin -Viusid in Metastatic Colorectal Adenocarcinoma


Brief description of study

The research product, registered as a nutritional supplement (Ocoxin, oral solution), manufactured by Laboratorios Catalysis S. L., comes in the form of single-dose vials of 30 ml. It will be used at a rate of 60 ml daily (1 vial every 12 hours). Our main objective is To evaluate the effect of Ocoxin-Viusid on the quality of life of patients with metastatic colorectal adenocarcinoma. Our hypothesis is that the administration of the nutritional supplement Ocoxin-Viusid it is expected to improve the quality of life and enhance tolerance to chemotherapy in at least 70% of patients.

Detailed Study Description

  • To evaluate the effect of Ocoxin-Viusid on the quality of life of patients.
    • To evaluate the influence of Ocoxin-Viusid on tolerance to onco-specific therapy.
    • Identify the changes that occur in the nutritional status of patients receiving the supplement.
    • To evaluate the toxicity of Ocoxin-Viusid in combination with chemotherapy in patients with metastatic colorectal adenocarcinoma.

Clinical Study Identifier: NCT03559543

Find a site near you

Start Over